Genetic Interaction between NRAS and BRAF Mutations and PTEN/MMAC1 Inactivation in Melanoma

Journal of Investigative Dermatology

Volumn 122, Issue 2, 2004, Pages 337-341

  Tsao, Hensin ^a,b   Goel, Vikas ^b   Wu, Heng ^b   Yang, Guang ^a   Haluska, Frank G ^b  

^a Wellman Laboratories   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

BRAF; Melanoma; NRAS; PTEN

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ARTICLE; CARCINOGENESIS; CELL CULTURE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; METASTASIS; MOLECULAR INTERACTION; ONCOGENE; ONCOGENE BRAF; ONCOGENE N RAS; PRIORITY JOURNAL;

EID: 1442274619     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0022-202X.2004.22243.x     Document Type: Article

References (26)

1. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ: Increasing complexity of Ras signaling. Oncogene 17:1395-1413, 1998
2. Cohen C, Zavala-Pompa A, Sequeira JH, et al: Mitogen-activated protein kinase activation is an early event in melanoma progression. Clin Cancer Res 8:3728-3733, 2002
3. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002
4. Dhawan P, Singh AB, Ellis DL, Richmond A: Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res 62:7335-7342, 2002
5. Diaz R, Ahn D, Lopez-Barcons L, et al: The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogene. Cancer Res 62:4514-4518, 2002
6. van Elsas A, Zerp SF, van der Flier S, et al: Relevance of ultraviolet-induced Nras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol 149:883-893, 1996
7. Govindarajan B, Bai X, Cohen C, et al: Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling. J Biol Chem 278:9790-9795, 2003
8. Graeven U, Rodeck U, Karpinski S, Jost M, Philippou S, Schmiegel W: Modulation of angiogenesis and tumorigenicity of human melanocytic cells by vascular endothelial growth factor and basic fibroblast growth factor. Cancer Res 61:7282-7290, 2001
9. Herlyn M, Satyamoorthy K: Activated ras: Yet another player in melanoma? Am J Pathol 149:739-744, 1996
10. Iwamoto T, Takahashi M, Ito M, et al: Aberrant melanogenesis and melanocytic tumour development in transgenic mice that carry a metallothionein/ret fusion gene. EMBO J 10:3167-3175, 1991
11. Kato M, Takahashi M, Akhand AA, et al: Transgenic mouse model for skin malignant melanoma. Oncogene 17:1885-1888, 1998
12. Maehama T, Dixon JE: The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273:13375-13378, 1998
13. Meier F, Nesbit M, Hsu MY, et al: Human melanoma progression in skin reconstructs: Biological significance of bFGF. Am J Pathol 156:193-200, 2000
14. Osaka M, Matsuo S, Koh T, Sugiyama T: Loss of heterozygosity at the N-ras locus in 7,12-dimethylbenz[a] anthracene-induced rat leukemia. Mol Carcinog 18:206-212, 1997
15. Pollock PM, Harper UL, Hansen KS, et al: High frequency of BRAF mutations in nevi. Nat Genet 33:19-20, 2003
16. Rodriguez-Viciana P, Marte BM, Warne PH, Downward J: Phosphatidylinositol 3′ kinase: One of the effectors of Ras. Philos Trans R Soc London B Biol Sci 351:225-231, discussion 231-222, 1996
17. Rodriguez-Viciana P, Warne PH, Khwaja A, et al: Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89:457-467, 1997
18. Saranath D, Chang SE, Bhoite LT, et al: High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco-related human oral carcinoma in India. Br J Cancer 63:573-578, 1991
19. Satyamoorthy K, Li G, Gerrero MR, et al: Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 63:756-759, 2003
20. Sukumar S, Armstrong B, Bruyntjes JP, Leav I, Bosland MC: Frequent activation of the Ki-ras oncogene at codon 12 in N-methyl-N-nitrosourea-induced rat prostate adenocarcinomas and neurogenic sarcomas. Mol Carcinog 4:362-368, 1991
21. Tsao H, Zhang X, Benoit E, Haluska FG: Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 16:3397-3402, 1998
22. Tsao H, Zhang X, Fowlkes K, Haluska FG: Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 60:1800-1804, 2000
23. Tsao H, Mihm MC, Sheehan C: PTEN expression in normal skin, acquired melanocytic nevi and cutaneous melanoma. J Am Acad Dermatol 49:865-872, 2003
24. Uribe P, Wistuba II, Gonzalez S: BRAF mutation: A frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol 25:365-370, 2003
25. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL: The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA 95:15587-15591, 1998
26. Zhou XP, Gimm O, Hampel H, Niemann T, Walker MJ, Eng C: Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 157:1123-1128, 2000